Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202087 | 0.85 | LMNA (0.47) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL31465506 | 0.85 | IMPDH2 (0.43) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL6168364 | 0.77 | IMPDH2 (0.65) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL16371297 | 0.77 | IMPDH2 (0.45) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL12907859 | 0.77 | IMPDH2 (0.60) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL12021891 | 0.77 | CFTR (0.44) | IMPDH2IMPDH1AAK1GAAALDH1A1 | |
| SCHEMBL30292019 | 0.74 | LMNA (0.58) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL6607846 | 0.74 | GAA (0.53) | IMPDH2IMPDH1LMNAPKMAAK1 | |
| SCHEMBL22170248 | 0.74 | LMNA (0.58) | IMPDH2IMPDH1LMNAPKMMAP4K4 | |
| SCHEMBL3466581 | 0.74 | LMNA (0.58) | IMPDH2IMPDH1LMNAPKMMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| EP-2331526-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-06-15 | — | — | EP | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| WO-2009158431-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | IMPDH2 68/4885IMPDH1 38/4885LMNA 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.